Meridian Bioscience's Q4 Earnings Beat Expectations

  • Meridian Bioscience Inc VIVO posted Q4 sales of $76.2 million, up 19% Y/Y, beating the consensus of $68.40 million.
  • Diagnostics segment net revenues increased 15% Y/Y to $34.3 million, led by a 22% increase in molecular products sales, and non-molecular assay products sales increased 14%, despite the impact of the LeadCare product recall.
  • The life Science segment delivered net revenues of $41.9 million, up 22% Y/Y.
  • The company reported an adjusted operating margin of 17%, down from 19% a year ago.
  • Adjusted EPS reached $0.23, higher than $0.19 a year ago, beating the consensus of $0.20.
  • It held cash and equivalents of $49.8 million as of September 30, 2021.
  • Guidance: Meridian Bioscience expects FY22 sales of $285 million - $300 million, lower than FY21 sales of $317.9 million and above the consensus of $283.27 million.
  • The company forecasts sales from the Diagnostics segment of $145 million - $150 million ($127.8 million in 2021) and the Life Science segment of $140 million - $150 million ($190.1 million in 2021).
  • For FY22, VIVO sees an adjusted operating margin of 21% - 22% and adjusted EPS of $0.98 - $1.08, versus the consensus of $1.07.
  • Price Action: VIVO shares are up 4.40% at $20.19 during the market session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: EarningsNewsGuidanceHealth CareSmall CapGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!